C hromosomal rearrangements involving the MLL gene are a characteristic feature of a variety of human leukemias, including acute lymphoid (ALL) and acute myeloid leukemias (AML) as well as secondary leukemias resulting from treatment with topoisomerase inhibitors. 1 The MEIS1 and HOXA9 genes have been shown to be major downstream targets of MLL fusion proteins. 2 The mammalian HOX genes encode DNA-binding homeobox proteins that have a role in developmental patterns and tissue fate during embryogenesis. MEIS1 is a homeodomain protein that acts as a DNA-binding cofactor of HOX proteins from paralog groups 9 through 13. 3 MEIS1 and HOXA genes are normally expressed in hematopoietic progenitor cells and their expression is down-regulated on differentiation. 4 Overexpression of MEIS1 and HOXA9 is seen in a variety of leukemic cell lines and primary AML samples, suggesting roles for these genes in leukemia initiation and maintenance. 5 In addition, fusion of HOXA9 to NUP98 in some AMLs further supports an important role for HOXA9 in leukemia. 6 In this issue of Blood, Faber et al ask if HOXA9 expression is required to maintain the leukemic state. 7 The authors investigated the effects of knocking down HOXA9 expression in MLL-rearranged and nonrearranged human leukemia cells. After shRNA-mediated HOXA9 suppression, induction of apoptosis and decreased colony formation were observed in leukemia cell lines. An increase of cells in the G 1 phase of the cell cycle and some cellular differentiation was also observed prior to the cells undergoing apoptosis. The apoptotic phenotype was rescued by expression of nontargetable HOXA9. The authors demonstrated that a greater induction of cell death was observed in MLL-rearranged cell lines and primary AML samples compared with MLL germ line cells after shRNA knockdown of HOXA9. In addition, the level of apoptosis positively correlated with levels of HOXA9 expression prior to shRNA knockdown. Gene expression profiling on MLL-rearranged cells after knockdown of HOXA9 expression showed decreased expression of genes, such as MEIS1 and PBX3, previously shown to play a role in leukemogenesis, suggesting these genes are downstream of HOXA9. Finally, MLLrearranged cells were subjected to knockdown of HOXA9 and transplanted into mice. These mice showed a significant decrease in leukemia burden, demonstrating that continued HOXA9 expression is required for survival and proliferation of human MLL-rearranged cells in vivo.
The results provided by Faber et al demonstrate that MLL-rearranged cells are addicted to HOXA9 expression to maintain their leukemic state, as shown in the figure. Another major downstream target of MLL fusion proteins is MEIS1. 2 Previous work done by Wong et al and work by Kumar et al used similar strategies to demonstrate that maintenance of the leukemic state in MLL-rearranged cells is also dependent on expression of MEIS1. 8, 9 Knockdown of MEIS1 expression results in decreased proliferation and survival of these cells. Although MEIS1 is important in maintenance of the leukemic state, elevated levels of MEIS1 are not sufficient to induce leukemia. 10 In contrast, elevated levels of HOXA9 are sufficient to induce leukemia with a long latency. 10 Coexpression of MEIS1 along with HOXA9, however, reduces the latency of HOX-induced leukemia. 4 Taken together, these data suggest a role for both MEIS1 and HOXA9 in leukemia initiation and maintenance.
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Tregs maintain self-tolerance and, although they are significantly deficient in patients with ITP, [1] [2] [3] [4] [5] [6] it now seems that their antigen-specific counterparts can be generated de novo from the patient's other nonregulatory T cells. This may set the future stage for platelet-induced cellular therapy as a treatment for ITP.
T he immune system has evolved several interactive peripheral regulatory mechanisms to protect against autoimmunity, and it has become increasingly clear that CD4 ϩ CD25 ϩ FoxP3 ϩ T regulatory cells (Tregs) are an important component of this control. 7, 8 Their importance in maintaining peripheral tolerance is exemplified by the observations, for example, that mutation of FoxP3 leads to widespread autoimmunity in the scurfy mouse and immune dysregulation, culminating in the X-linked syndrome (IPEX) in humans. 7, 8 Treg deficiencies have been found in several autoimmune diseases including the autoimmune bleeding disorder, idiopathic thrombocytopenic purpura (ITP). It is currently thought that this deficiency is at the center of immune dysregulation and stimulation of autoimmune attack. [1] [2] [3] [4] [5] [6] Tregs can be generally divided into 2 flavors depending on their ontogeny and mode of action. For example, natural (n) Tregs are generated in the thymus and are generally anergic to antigenic stimulation but can effectively inhibit proliferation of CD4 ϩ T helper cells via direct cell contact. 7 Thus, the ability to isolate these nTregs holds the promise of immunosuppressive therapy, however, since they constitute only 3% of circulating CD4 ϩ T cells, their numbers are far too small to be clinically effective. On the other hand, inducible (i) Tregs can be generated in the periphery from nonregulatory CD4 ϩ CD25 Ϫ T cells and, although they share the phenotype and in vitro suppressive activities of nTreg, they are activated in an antigen-specific fashion. Nonetheless, although iTregs can be induced from CD4 ϩ T cells, less is known about whether these cells function in healthy subjects or more importantly, whether they could be expanded from the peripheral blood of patients with autoimmune diseases known to be associated with deficiencies in Tregs. [1] [2] [3] [4] [5] [6] [7] In this issue, Zhang and colleagues address the latter possibility by studying whether iTregs could be stimulated in vitro from the peripheral blood of patients with ITP and whether the in vitro expanded cells were functional. 9 What they found is fuel for the notion that ITP is not only a complex immunoregulatory disorder involving several cellular and soluble elements, but that perhaps an effective autologous cellular therapy for ITP could be developed.
The authors studied 41 newly diagnosed patients with chronic ITP. They found that platelet glycoprotein (GP)-specific induced iTregs could be generated de novo from nonregulatory CD4 ϩ CD25 Ϫ CD45RA ϩ cells and could mediate both antigen-specific and linked suppression of proliferating antiplatelet CD4 ϩ T helper cells in vitro. Using a series of culturing techniques, they more importantly demonstrated that the expanded iTregs mediated their suppressive effects on T cells by actually modulating the T-cell stimulatory capacity of dendritic cells (DCs). This modulating effect was dependent on the presence of TGF-␤, a potent immunosuppressive and tolerance-inducing cytokine. In an attempt to determine how the iTregs modulated DCs, they performed a genome-wide assessment of the DCs using microarrays and found that Toll-like receptor, Notch, and TGF-beta signaling pathways were related to the DC's ability to invoke suppression. How these particular signaling pathways within the iTregmodified DCs affect the changes in their T-cell stimulatory capacity is still not known but these pathways are known to be intimately associated with both pro-and anti-inflammatory responses. It may be that the balance between these intracellular DC pathways ultimately controls the development of platelet autoimmunity. These findings not only increase our knowledge of how platelet-specific T-cell responses are regulated in patients with ITP but they shed light on the potential of producing antigenspecific iTregs from the patients in vitro for the purpose of antigen-targeted cellular immunotherapy.
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